IMMUNIC, INC.(IMUX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IMUX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for IMMUNIC, INC. (IMUX), a Healthcare sector company. IMUX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), IMMUNIC, INC. reports net income of $-34.1M, free cash flow of $-31.2M. Top institutional holders of IMUX by reported 13-F value include abrdn plc, BVF, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. IMUX trades on the Nasdaq exchange and files with the SEC under CIK 1280776. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMUX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUNIC, INC. directly from SEC EDGAR.
Net Income
Q2 2026
$-34.1M
Free Cash Flow
Q2 2026
$-31.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+3.3% YoYOperating Income
-5.3% YoYEPS (Diluted)
+38.0% YoYTotal Assets
-41.1% YoYOp. Cash Flow
-1.2% YoYFree Cash Flow
-1.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-97.2M +3.3% | $-100.5M -7.4% | $-93.6M +22.3% | $-120.4M -29.5% | $-92.9M -111.2% | $-44.0M |
| Operating Income | $-103.2M -5.3% | $-98.1M +1.2% | $-99.2M +17.0% | $-119.5M -30.4% | $-91.7M -87.2% | $-49.0M |
| EPS (Diluted) | $-0.62 +38.0% | $-1.00 +52.6% | $-2.11 +44.2% | $-3.78 +3.8% | $-3.93 -39.9% | $-2.81 |
| Total Assets | $24.1M -41.1% | $40.9M -24.7% | $54.3M -57.5% | $127.8M -8.2% | $139.1M -17.1% | $167.9M |
| Operating Cash Flow | $-85.8M -1.2% | $-84.8M -19.7% | $-70.8M -8.7% | $-65.1M +21.7% | $-83.2M -80.5% | $-46.1M |
| Free Cash Flow | $-86.0M -1.1% | $-85.0M -19.5% | $-71.2M -9.1% | $-65.3M +21.7% | $-83.3M -80.0% | $-46.3M |
Get alerted when IMUX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IMMUNIC, INC. including:
Top Institutional Holders of IMUX
abrdn plc
$12.7M824,393 shBVF INC/IL
$11.8M765,295 shMILLENNIUM MANAGEMENT LLC
$11.4M740,347 shAvidity Partners Management LP
$10.3M669,941 shBRAIDWELL LP
$9.9M645,010 shLaurion Capital Management LP
$9.4M610,326 shVANGUARD CAPITAL MANAGEMENT LLC
$8.8M571,561 shJones Hill Capital LP
$8.3M539,814 shWoodline Partners LP
$7.2M471,528 shSoleus Capital Management, L.P.
$6.9M450,000 sh
| Fund | Value | Shares |
|---|---|---|
| abrdn plc | $12.7M | 824,393 |
| BVF INC/IL | $11.8M | 765,295 |
| MILLENNIUM MANAGEMENT LLC | $11.4M | 740,347 |
| Avidity Partners Management LP | $10.3M | 669,941 |
| BRAIDWELL LP | $9.9M | 645,010 |
| Laurion Capital Management LP | $9.4M | 610,326 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.8M | 571,561 |
| Jones Hill Capital LP | $8.3M | 539,814 |
| Woodline Partners LP | $7.2M | 471,528 |
| Soleus Capital Management, L.P. | $6.9M | 450,000 |
More Healthcare Companies
View all Healthcare →Put IMUX on your watchlist
Track score changes the day IMMUNIC, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMUX a good stock to buy?
13F Pro's AI-powered analysis of IMMUNIC, INC. (IMUX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMUX are available on the IMUX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMUX is classified as a small company.
Which hedge funds own IMUX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMUX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMMUNIC, INC.'s investment landscape.